<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65424">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874938</url>
  </required_header>
  <id_info>
    <org_study_id>15007</org_study_id>
    <secondary_id>I4C-JE-JTBE</secondary_id>
    <nct_id>NCT01874938</nct_id>
  </id_info>
  <brief_title>A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer</brief_title>
  <official_title>A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants
      with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ)
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) Rate</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Exhibit Confirmed Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])</measure>
    <time_frame>Baseline to Confirmed CR or PR (Estimated up to 4 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Exhibit Stable Disease (SD) or Confirmed CR or PR (Disease Control Rate [DCR])</measure>
    <time_frame>Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 4 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Date of CR or PR to Date of Measured Recurrent or Progressive Disease or Death from Any Cause (Estimated up to 4 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Death from Any Cause (Estimated up to 6 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Systemic Clearance (CL) of LY287358</measure>
    <time_frame>Baseline to Study Completion (Estimated up to 4 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK):  Volume of distribution (V) of LY287358</measure>
    <time_frame>Baseline to Study Completion (Estimated up to 4 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 6 Months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>LY2875358</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY2875358</intervention_name>
    <arm_group_label>LY2875358</arm_group_label>
    <other_name>Administered IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of a histopathologically or cytologically confirmed local and/or
             advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma which is
             unresectable

          -  Have received 2 regimens of prior chemotherapies for gastric or GEJ adenocarcinoma

          -  Have the presence of measurable disease as defined by the Response Evaluation
             Criteria in Solid Tumors (RECIST 1.1)

          -  Have consent to provide a tissue sample for pre-screening

          -  Determined to be MET diagnostic positive based upon testing of a tumor sample
             obtained at any time before enrollment

          -  Have discontinued all previous treatments for cancer, including chemotherapy and
             radiotherapy, for at least 3 weeks before enrollment and  have recovered from the
             acute effects of therapy

          -  Have adequate organ function

          -  Male participants: must agree to use a reliable method of birth control and to not
             donate sperm during the study and for at least 4 months following last dose of study
             drug or country requirements, whichever is longer

          -  Female participants: are women of child-bearing potential who test negative for
             pregnancy ≤14 days before enrollment based on a serum pregnancy test and agree to use
             a reliable method of birth control during the study and for 4 months following the
             last dose of the study drug and must also not be breastfeeding

          -  Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
             scale

          -  Have an estimated life expectancy, in the judgment of the investigator, of at least
             12 weeks

        Exclusion Criteria:

          -  Are currently enrolled in, or discontinued within the last 21 days from, a clinical
             trial involving an investigational product or non-approved use of a drug or device,
             or concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study

          -  Have previously completed or withdrawn from this study or any other study
             investigating LY2875358

          -  Have an active fungal, bacterial, and/or known viral infection

          -  Have a history of New York Heart Association class ≥3, unstable angina, myocardial
             infarction (MI) in 6 months prior to study drug administration

          -  Have symptomatic central nervous system (CNS) malignancy or metastasis

          -  Have previous or concurrent malignancies

          -  Have received a liver transplant, or have liver cirrhosis with a Child-Pugh Stage of
             B or C

          -  Have corrected QT interval (QTc) of &gt;470 millisecond (msec) on screening
             electrocardiogram (ECG)

          -  Have received previous treatment with any hepatocyte growth  factor (HGF)/MET
             targeting therapeutics

          -  Have a history of radiation therapy involving more than 25% of the bone marrow.
             Previous radiation therapy is allowed but should have been limited and must not have
             included whole pelvis radiation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>4648681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>060</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>135 720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
